Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells

Pancreatic adenocarcinoma has an exceedingly poor prognosis, accounting for five-year survival of less than 5%. Presently, improving the efficacy of pancreatic adenocarcinoma treatment has been the focus of medical researchers worldwide. Recently, it has been suggested that deregulation of interleuk...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2018-01, Vol.2018 (2018), p.1-10
Main Authors: Li, Da, Zhai, Chong-Ya, Hu, Hong, Wang, Jing, Tong, Mengting, Xing, Hai-Bo, Huang, Chang-Xin
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Anticancer properties
Antimetabolites, Antineoplastic - pharmacology
Antitumor activity
Apoptosis
Apoptosis - drug effects
Apoptosis - genetics
Biomedical research
Cancer
Carcinogenesis - drug effects
Carcinogenesis - genetics
Cell Line, Tumor
Cell proliferation
Cell Proliferation - drug effects
Cell Proliferation - genetics
Chemosensitization
Cytokines
Deoxycytidine - analogs & derivatives
Deoxycytidine - pharmacology
Deregulation
Development and progression
Experiments
Flow cytometry
Gemcitabine
Genes
Genetic aspects
Health aspects
Humans
Interleukin 6
Interleukin-6 - genetics
Interleukins
Kinases
Medical prognosis
Medical research
Pancreatic cancer
Pancreatic Neoplasms
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - genetics
Plasmids
Prognosis
RNA, Small Interfering - genetics
Rodents
Tissues
Tumorigenicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic adenocarcinoma has an exceedingly poor prognosis, accounting for five-year survival of less than 5%. Presently, improving the efficacy of pancreatic adenocarcinoma treatment has been the focus of medical researchers worldwide. Recently, it has been suggested that deregulation of interleukin- (IL-) 6 is caused by a key gene involved in the beginning and development of pancreatic adenocarcinoma. Herein, we investigated whether suppression of IL-6 could augment gemcitabine sensitivity in the PANC-1 cells. We found considerably higher expression of IL-6 in pancreatic adenocarcinoma tissues than that in the adjacent nontumorous tissues. Suppression of IL-6 by shRNA resulted in apoptosis as well as inhibition of cell proliferation and tumorigenicity. In addition, suppression of IL-6 remarkably promoted antitumor effect of gemcitabine, indicating that the combination of shRNA targeting IL-6 with gemcitabine may provide a potential clinical approach for pancreatic cancer therapy.
ISSN:2314-6133
2314-6141
DOI:10.1155/2018/3195025